OINDP development specialist Nanopharm has appointed Arron Danson as Head of Device Development, the company said. Danson has extensive experience in the development of pulmonary and nasal delivery devices, having worked at companies such as Vectura, Coalesce Product Development, and, most recently, Kinneir Dufort.
Nanopharm, which announced the appointment of Mark Clement as Chairman of the Board in September 2016, offers OINDP development services from early development through to regulatory approval of the drug and device.
Nanopharm co-Founder and Director Rob Price said, “Arron’s appointment enables Nanopharm to provide an integrated approach to orally inhaled and nasal drug product development. Hitherto, device development and formulation optimization are not typically integrated during the development cycle, which adds significant risk to OINDP programs. The combination of Nanopharm’s core strengths in material science, formulation development and device development, will de-risk and expedite product development programs of our growing client base.”
Managing Director Jag Shur commented, “Arron’s broader skills in project management will also provide us with industry leading standards and protocols as we continue to build our fee for service and co-development business. By combining device and formulation capabilities, Nanopharm aims to become the leading provider of integrated drug delivery solutions for OINDPs.”
Read the Nanopharm press release.
